JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 20, 2007; DOI: 10.1124/jpet.107.131896

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.131896v1
324/2/475    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munoz-Luque, J.
Right arrow Articles by Jimenez, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munoz-Luque, J.
Right arrow Articles by Jimenez, W.


Received for publication September 20, 2007.
Revised November 15, 2007.
Accepted for publication November 19, 2007.

REGRESSION OF FIBROSIS AFTER CHRONIC STIMULATION OF CANNABINOID CB2 RECEPTOR IN CIRRHOTIC RATS

Javier Munoz-Luque 1, Josefa Ros 1, Guillermo Fernandez-Varo 1, Sonia Tugues 1, Manuel Morales-Ruiz 1, Carlos E Alvarez 2, Scott L Friedman 2, Vicente Arroyo 1, Wladimiro Jimenez 1*

1 Hospital Clinic 2 Mount Sinai School of Medicine

* Address correspondence to: E-mail: wjimenez{at}clinic.ub.es

Abstract

Two cannabinoid receptor subtypes, CB1 and CB2, have been cloned and characterized. Among other activities, receptor activation by cannabinoid ligands may result in pro or antifibrogenic effects depending on their interaction with CB1 or CB2, respectively. In the current study we investigated whether selective activation of hepatic CB2 modifies collagen abundance in cirrhotic rats with ascites. mRNA and protein expression of CB receptors in the liver of control and cirrhotic rats was assessed by RT-PCR, Western blot and immunohistochemistry. The effect of chronically activating the CB2 receptor was investigated in cirrhotic rats with ascites treated daily (9 days) with the CB2 receptor selective agonist JWH-133. At the end of treatment, mean arterial pressure and portal pressure were measured and liver samples were obtained to evaluate infiltrate of mononuclear cells, hepatic apoptosis, {alpha}-SMA expression, collagen content and MMP-2 abundance in all animals. JWH-133 improved arterial pressure, decreased the inflammatory infiltrate, reduced the number of activated stellate cells, increased apoptosis in non-parenchymal cells located in the margin of the septa, and decreased fibrosis as compared to cirrhotic rats treated with vehicle. This was associated with decreased {alpha}-SMA and collagen I and increased MMP-2 in the hepatic tissue of cirrhotic rats treated with the CB2 agonist compared to untreated cirrhotic animals. Therefore, selective activation of hepatic CB2 receptors significantly reduces hepatic collagen content in rats with pre-existing cirrhosis, thus raising the possibility of using selective CB2 agonists for the treatment of hepatic fibrosis in human cirrhosis.


Key words: CB2, JWH-133, cannabinoid, chronic, cirrhosis, regression


This article has been cited by other articles:


Home page
 GutHome page
A A Izzo and M Camilleri
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
Gut, August 1, 2008; 57(8): 1140 - 1155.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.